arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

download Export Data

Fulcrum Therapeutics, Inc.

FULC

$3.89 ▲ +0.12 (+3.05%) at close

9 Visible periods

23 Metrics

Peer-ranked Benchmarks

Price Chart

Health

Poor

Neutral

auto_awesome

Analytical Summary

Fulcrum Therapeutics, Inc. shows mixed fundamentals. Consider comparing against peers in the Healthcare sector before making investment decisions.

Market Cap —

Dividend Yield —

Revenue Growth N/M

Op. Margin None

ROIC -19.2% ↘

FCF / Share —

Trailing P/E —

Price / Book 0.7x

FCF Yield —

Debt / Equity —

info Valuation on last close. End-of-day price, Aug 7, 2026.

9-Year Financial Trajectory

Annual

Metric Value Trend Year over Year Percentile

Revenue Total top-line sales

$0.00

↓ -100.0% —

Net Income Profit after all expenses

$-74.88M

↓ -670.0% —

Operating Margin Operating profit as % of sales

-27.4%

↑ +93.5% —

Health Breakdown

Returns ↑

Cash Quality ↓

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 4 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗
Revenue Growth YoY (%)	N/M	2752.0% Excellent ↑ Excellent Improving Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+34301%)	-55.8% Weak ↓ Weak Declining Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-797%)	-66.9% Weak Weak Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-936%)	117.2% Excellent Excellent Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+1365%)	—	—	—	—
EPS Growth YoY (%)	-637.5% Weak ↓ Weak Declining Year-over-year change in earnings per share Optimal: > 10%	89.9% Excellent ↑ Excellent Improving Year-over-year change in earnings per share Optimal: > 10%	34.8% Excellent Excellent Year-over-year change in earnings per share Optimal: > 10%	-6.6% Weak Weak Year-over-year change in earnings per share Optimal: > 10%	—	—	—	—	—
Net Income Growth YoY (%)	-670.0% Weak ↓ Weak Declining Year-over-year change in net income	90.0% Excellent ↑ Excellent Improving Year-over-year change in net income	11.4% Fair ↑ Fair Improving Year-over-year change in net income	-35.9% Weak ↑ Weak Improving Year-over-year change in net income	-14.2% Weak ↑ Weak Improving Year-over-year change in net income	14.3% Fair Fair Year-over-year change in net income	-153.7% Weak Weak Year-over-year change in net income	—	—
Revenue CAGR 3Y (%)	—	61.0% Excellent Excellent Compound annual revenue growth over 3 years	-31.7% Weak Weak Compound annual revenue growth over 3 years	—	—	—	—	—	—

💰 Are margins durable? 4 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗
Operating Margin (%) (%)	—	-27.4% Weak Weak Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-282%)	—	—	-423.0% Weak Weak Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-2920%)	—	—	—	—
Profit Margin (%) (%)	—	-12.2% Weak Weak Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-201%)	—	—	-421.9% Weak Weak Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-3616%)	—	—	—	—
FCF Margin (%) (%)	—	-3.1% Weak Weak Free cash flow as a percentage of revenue Optimal: > 10%	—	—	-418.5% Weak Weak Free cash flow as a percentage of revenue Optimal: > 10%	—	—	—	—
FCF / Net Income (x)	0.81x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.26x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	0.94x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.90x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.99x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.78x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.49x Weak Weak Free cash flow relative to reported net income Optimal: > 1x	0.97x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	—

🎯 Is capital allocation efficient? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗
Return on Invested Capital (%)	-19.2% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-7.1% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-37.2% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-44.7% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-30.3% Weak → Weak Stable Return earned on debt + equity capital invested Optimal: > 10%	-59.4% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-76.3% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	41.6% Excellent Excellent Return earned on debt + equity capital invested Optimal: > 10%	—
Return on Capital (%) (%)	-23.1% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-8.4% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-42.9% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-49.7% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-34.5% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-55.3% Weak → Weak Stable Operating profit relative to total assets Optimal: > 10%	-76.3% Weak Weak Operating profit relative to total assets Optimal: > 10%	-39.1% Weak Weak Operating profit relative to total assets Optimal: > 10%	—
Return on Common Equity (%) (%)	-21.5% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-243%)	-4.0% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-127%)	-41.4% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-376%)	-55.2% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-468%)	-38.2% Weak → Weak Stable Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-355%)	-74.4% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-596%)	-94.9% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-732%)	51.2% Excellent Excellent Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+241%)	—

⚖️ Is the balance sheet risky? 2 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗
Interest Coverage (x)	—	—	—	—	—	-17902.75x Weak ↓ Weak Declining Operating income divided by interest expense Optimal: > 5x	-12031.00x Weak Weak Operating income divided by interest expense Optimal: > 5x	-3349.80x Weak Weak Operating income divided by interest expense Optimal: > 5x	—
Net Debt (USD)	$-197.53M	$-58.21M	$-25.56M	$-35.10M	$-35.41M	$-57.05M	$-96.71M	$-72.80M	—

📊 What does each share earn? 4 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗
Basic EPS, GAAP (USD)	$-1.18	$-0.16	$-1.59	$-2.44	$-2.29	—	—	—	—
Book Value per Share (USD)	$5.24	$4.50	$3.80	$3.82	$5.21	$3.41	$3.85	$-40.10	—
Tangible Book Value per Share (USD)	$5.24	$4.50	$3.80	$3.82	$5.21	$3.41	$3.85	$-40.10	—
Basic Weighted Avg Shares (shares)	63,355	61,984	61,310	44,991	35,361	—	—	—	—

🏦 How resilient is the balance sheet? 2 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗
Working Capital (USD)	$344.43M	$238.88M	$228.52M	$190.79M	$206.80M	$92.78M	$87.94M	$69.87M	—
Total Equity (USD)	$349.00M	$243.03M	$235.19M	$198.94M	$211.54M	$95.18M	$87.15M	$-63.67M	$-33.27M

📋 What is driving earnings? 4 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗
Sales/Revenue/Turnover (USD)	$0.00	$80.00M	$2.81M	$6.34M	$19.16M	$8.82M	—	—	—
Depreciation Expense (USD)	$1.39M	$1.59M	$2.17M	$2.41M	$2.52M	$2.38M	$2.05M	$1.34M	—
Net Income, GAAP (USD)	$-74.88M	$-9.72M	$-97.33M	$-109.87M	$-80.85M	$-70.82M	$-82.68M	$-32.59M	—
Operating Cash Flow (USD)	$-60.06M	$-2.22M	$-90.97M	$-97.05M	$-78.48M	$-53.66M	$-39.48M	$-22.56M	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 9 years · 35 quarters

Fulcrum Therapeutics, Inc.

Analytical Summary

9-Year Financial Trajectory

Health Breakdown

Statement lens

Benchmark Lens

Percentile Rankings

Peer Comparison

Compare FULC with peers